{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:14:31Z","timestamp":1773152071755,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ygyno.2025.10.022","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:34:36Z","timestamp":1761867276000},"page":"90-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment"],"prefix":"10.1016","volume":"203","author":[{"given":"Auni","family":"Lindgren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk","family":"Benseler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liat","family":"Hogen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taymaa","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Laframboise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve","family":"Bouchard-Fortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Avery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus Q.","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2025.10.022_bb0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.10.022_bb0010","series-title":"SEER*Explorer: An Interactive Website for SEER Cancer Statistics [Internet]","year":"2023"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2025.10.022_bb0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"26","key":"10.1016\/j.ygyno.2025.10.022_bb0020","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2025.10.022_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2025.10.022_bb0030","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.10.022_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"1125","key":"10.1016\/j.ygyno.2025.10.022_bb0040","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210117","article-title":"The role of CT, PET-CT, and MRI in ovarian cancer","volume":"94","author":"Engbersen","year":"2021","journal-title":"Br. J. Radiol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.10.022_bb0045","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ygyno.2020.03.003","article-title":"Prognostic value of radiological recurrence patterns in ovarian cancer","volume":"157","author":"Roze","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.10.022_bb0050","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2011.09.011","article-title":"Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer","volume":"124","author":"Tanner","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.10.022_bb0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2012.05.026","article-title":"Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy","volume":"127","author":"Esselen","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.10.022_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ijgo.13813","article-title":"Efficacy and toxicity of intraperitoneal chemotherapy as compared to intravenous chemotherapy in the treatment of patients with advanced ovarian cancer","volume":"157","author":"Kim","year":"2022","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"6","key":"10.1016\/j.ygyno.2025.10.022_bb0065","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"18","author":"von Elm","year":"2007","journal-title":"Epidemiology"},{"issue":"20","key":"10.1016\/j.ygyno.2025.10.022_bb0070","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","article-title":"Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels","volume":"19","author":"Rustin","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.10.022_bb0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2025.10.022_bb0080","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","author":"Dedrick","year":"1978","journal-title":"Cancer Treat. Rep."},{"issue":"7","key":"10.1016\/j.ygyno.2025.10.022_bb0085","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0024-3205(95)02200-7","article-title":"Pharmacokinetic and pharmacodynamic optimization of intraperitoneal chemotherapy","volume":"58","author":"Balthasar","year":"1996","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.ygyno.2025.10.022_bb0090","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF00686048","article-title":"Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment","volume":"25","author":"Los","year":"1990","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.ygyno.2025.10.022_bb0095","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","article-title":"Phase I trial of intraperitoneal taxol: a gynecoloic oncology group study","volume":"10","author":"Markman","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.10.022_bb0100","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","article-title":"Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a gynecologic oncology group pilot study","volume":"13","author":"Francis","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.10.022_bb0105","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","volume":"2016","author":"Jaaback","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.ygyno.2025.10.022_bb0110","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200225","article-title":"Intraperitoneal carboplatin for ovarian cancer - a phase 2\/3 trial","volume":"2","author":"Nagao","year":"2023","journal-title":"NEJM Evid."},{"issue":"1","key":"10.1016\/j.ygyno.2025.10.022_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2005.12.006","article-title":"Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma","volume":"100","author":"Trimble","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2025.10.022_bb0120","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology\/Gynecologic oncology group study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:35:18Z","timestamp":1773095718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825010467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"alternative-id":["S0090825825010467"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.10.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}